Merrill keeps Genzyme at buy

Genzyme Corp. was maintained at its buy rating by Merrill Lynch analyst Eric Ende after the company reported third-quarter earnings per share of $0.73, in line with the analyst's expectations. Product sales were mostly in line with analyst estimates with the exception of Synvisc. The stock may show weakness on concerns around the PhosLo acquisition by Fresenius and due to price caps by Genentech on Avastin. Shares of the Cambridge, Mass.-based biotechnology company were up 39 cents, or 0.58%, at $67.29. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.